Literature DB >> 20647493

Sustained administration of trazodone enhances serotonergic neurotransmission: in vivo electrophysiological study in the rat brain.

Ramez Ghanbari1, Mostafa El Mansari, Pierre Blier.   

Abstract

Despite its clinical use for more than two decades, the mechanisms by which trazodone acts as an antidepressant are not clear, because it has affinity for a variety of 5-hydroxytryptamine (5-HT; serotonin) receptors and the 5-HT transporter. This study examined the effects of sustained trazodone administration on 5-HT neurotransmission. Electrophysiological recordings were conducted in anesthetized rats. Subcutaneously implanted minipumps delivered vehicle or trazodone (10 mg/kg/day) for 2 and 14 days. A 2-day trazodone administration suppressed the firing rate of raphe 5-HT neurons, which recovered to baseline after 14 days. This was attributable to 5-HT(1A) autoreceptor desensitization because the suppressant effect of the 5-HT autoreceptor agonist lysergic acid diethylamide was dampened in 14-day trazodone-treated rats. Prolonged trazodone administration did not change the sensitivity of postsynaptic 5-HT(1A) and α(2)-adrenergic receptors in hippocampus, but enhanced synaptic 5-HT levels because the 5-HT(1A) antagonist N-{2-[4 (2-methoxyphenyl)-1-piperazinyl]ethyl}-N-(2-pyridinyl) cyclohexanecarboxamide trihydrochloride (WAY-100635) enhanced hippocampal firing in treated rats, but not in controls. Trazodone administration for 14 days increased the 50% recovery time value, an index of 5-HT transporter blockade in vivo, and decreased the inhibitory function of terminal 5-HT(1B) autoreceptors on the electrically evoked release of 5-HT. The agonistic action of trazodone at 5-HT(1A) receptors was characterized as being full because it did not attenuate the inhibitory action of 5-HT when coapplied locally. The enhanced 5-HT neurotransmission by trazodone is caused in part by reuptake blockade and activation of postsynaptic 5-HT(1A) receptors, which may account for its effectiveness in major depression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20647493     DOI: 10.1124/jpet.110.169417

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  Serotonin and beyond: therapeutics for major depression.

Authors:  Pierre Blier; Mostafa El Mansari
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-25       Impact factor: 6.237

2.  Brexpiprazole Alters Monoaminergic Systems following Repeated Administration: an in Vivo Electrophysiological Study.

Authors:  Chris A Oosterhof; Mostafa El Mansari; Christoffer Bundgaard; Pierre Blier
Journal:  Int J Neuropsychopharmacol       Date:  2015-10-01       Impact factor: 5.176

3.  Toxic Effects of Trazodone on Male Reproductive System via Disrupting Hypothalamic-Pituitary-Testicular Axis and Inducing Testicular Oxidative Stress.

Authors:  Sinem Ilgın; Gözde Aydoğan-Kılıç; Merve Baysal; Volkan Kılıç; Mina Ardıç; Şeyda Uçarcan; Özlem Atlı
Journal:  Oxid Med Cell Longev       Date:  2018-07-29       Impact factor: 6.543

Review 4.  In vivo electrophysiological recordings of the effects of antidepressant drugs.

Authors:  Paul J Fitzgerald; Brendon O Watson
Journal:  Exp Brain Res       Date:  2019-05-11       Impact factor: 1.972

5.  Dual inhibitory action of trazodone on dorsal raphe serotonergic neurons through 5-HT1A receptor partial agonism and α1-adrenoceptor antagonism.

Authors:  Alberto Montalbano; Boris Mlinar; Francesco Bonfiglio; Lorenzo Polenzani; Maurizio Magnani; Renato Corradetti
Journal:  PLoS One       Date:  2019-09-26       Impact factor: 3.240

6.  Adjunctive Trazodone and Depression Outcome in Adolescents Treated with Serotonin Re-uptake Inhibitors.

Authors:  Meshal A Sultan; Darren B Courtney
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2017-10-01

7.  Computational Model of Antidepressant Response Heterogeneity as Multi-pathway Neuroadaptation.

Authors:  Mariam B Camacho; Thomas J Anastasio
Journal:  Front Pharmacol       Date:  2017-12-20       Impact factor: 5.810

8.  A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder.

Authors:  Andrea Fagiolini; Umberto Albert; Laura Ferrando; Erik Herman; Cosmina Muntean; Eva Pálová; Agnese Cattaneo; Alessandro Comandini; Giorgio Di Dato; Giorgio Di Loreto; Luisa Olivieri; Enrica Salvatori; Serena Tongiani; Siegfried Kasper
Journal:  Int Clin Psychopharmacol       Date:  2020-05       Impact factor: 2.023

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.